Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
The EU approved Enhertu (trastuzumab deruxtecan) as adjuvant monotherapy for adults with resected HER2-positive early breast cancer and residual invasive disease after neoadjuvant treatment.
The approval covers patients with residual disease after neoadjuvant treatment and is based on results from the DESTINY-Breast05 phase 3 trial.